Lord, Abbett & Co
CYTK icon

Lord, Abbett & Co’s Cytokinetics CYTK Stock Holding History

Lord, Abbett & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-198,158
Closed -$13.9M – 531
2024
Q1 		$13.9M Sell
198,158
-1,409,654
-88% -$109M 0.04% 359
2023
Q4 		$134M Buy
1,607,812
+1,006,641
+167% +$36.5M 0.47% 56
2023
Q3 		$17.7M Sell
601,171
-1,089,299
-64% -$36.3M 0.07% 342
2023
Q2 		$55.1M Sell
1,690,470
-616,799
-27% -$22.8M 0.19% 165
2023
Q1 		$81.2M Sell
2,307,269
-617,042
-21% -$25.2M 0.29% 99
2022
Q4 		$134M Sell
2,924,311
-834,311
-22% -$35.9M 0.48% 47
2022
Q3 		$182M Buy
3,758,622
+768,471
+26% +$37M 0.67% 26
2022
Q2 		$117M Buy
2,990,151
+732,147
+32% +$29.5M 0.42% 57
2022
Q1 		$83.1M Buy
2,258,004
+1,424,936
+171% +$50.6M 0.22% 129
2021
Q4 		$38M Buy
+833,068
New +$32.1M 0.09% 308

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Lord, Abbett & Co's CYTK Position: Q2 2024 in Review

Lord, Abbett & Co sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 198,158 shares — an estimated $13.9M sold.

Lord, Abbett & Co first reported a position in CYTK in Q4 2021 and held it in 10 quarters. The position peaked at $182M in Q3 2022. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • Lord, Abbett & Co reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 198,158 Cytokinetics shares in Q2 2024, an estimated $13.9M.
  • Lord, Abbett & Co first reported a position in Cytokinetics in Q4 2021 and held it in 10 quarters.
  • Lord, Abbett & Co's Cytokinetics position peaked at $182M in Q3 2022.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Lord, Abbett & Co's 13F filing for Q2 2024, filed 14 Aug 2024.